2.1. Design
dementia-like, dementia, end-stage organ failure, chronic disease
HEART DISEASE, DISEASE, NEURODEGENERATIVE DISEASES, CHRONIC RENAL DISEASE, PCP, CHRONIC LIVER DISEASE, CHRONIC DISEASE
This study was a parallel-group, unblinded, randomized clinical trial conducted in a subacute hospital in Gipuzkoa, Spain. Participants were randomly selected to receive either the usual pharmaceutical care (control group) or an adapted PCP model (intervention group). The trial was registered with ClinicalTrials.gov (NCT05454644). Specifically, in this post hoc study, the effect of the PCP model on different disease trajectories has been compared, establishing two groups: (1) dementia-like trajectory, including patients with dementia or neurodegenerative diseases or those who, without being notable for an advanced chronic disease, had been identified as in the final phase of life; and (2) end-stage organ failure trajectory, including chronic pulmonary disease, chronic heart disease, serious chronic liver disease, and serious chronic renal disease. For the comparative analysis based on the state of frailty, the cut-off point was established as a Frail-VIG score of 0.5, arbitrarily based on previous studies [All participants were aged ≥65 years and admitted to the geriatric convalescence unit, where they were identified according to their baseline in the first 24–72 h as having a non-oncological advanced chronic disease and needing palliative care, with a limited survival prognosis according to the Necessity of Palliative Care (NECPAL) test [